On 7 September 2026, LONGBIO-B (01779.HK) voluntarily announced that it had been included in the eligible securities lists under the Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect schemes, effective from the same day, pursuant to the notices issued by the Shanghai and Shenzhen stock exchanges. Eligible mainland investors will be able to trade the company's shares directly through the two exchanges, and the company expects the inclusion to broaden its shareholder base and improve share liquidity.
On 7 September 2026, LONGFOR GROUP (00960.HK) announced its unaudited operational data for August 2026: contracted sales of RMB 2.20 billion with contracted sales area of 250,000 sq.m. in the month (RMB 1.50 billion attributable to shareholders' interests), and cumulative total contracted sales of RMB 20.84 billion with contracted sales area of 2,239,000 sq.m. for the eight months ended 31 August 2026, together with operations and services revenue (exclusive of tax) of approximately RMB 18.18 billion over the same period.
On 7 September 2026, ESTUN (02715.HK) announced the completion of its acquisition of 100% equity in Estun Kuzhuo on 2 September 2026 in accordance with the acquisition agreement, making it an indirect wholly-owned subsidiary consolidated into the group's financial statements. The cash acquisition, with a total consideration of RMB 487.10 million, was approved by the board and the extraordinary shareholders' meeting and constitutes a connected transaction.
On 7 September 2026, MINIEYE (02431.HK) voluntarily announced that chairman, executive director and general manager Dr. Liu Guoqing had purchased 100,000 H shares on the open market at an average price of approximately HKD 2.3835 per share, representing approximately 0.02% of the issued shares. Following the purchase, his beneficial holdings increased to 34,583,503 shares (approximately 7.8%), with aggregate holdings of approximately 17.55% together with his concert parties.
On 7 September 2026, CICC (03908.HK) announced that the CSRC had issued an approval (Zhengjian Xuke [2026] No. 2377) approving and consenting to the registration of its merger by absorption of Dongxing Securities and Cinda Securities together with related shareholding changes, satisfying the CSRC approval condition for the merger agreement. The company also set out its cash election arrangements: with the 2025 final dividend paid, the cash prices have been adjusted to RMB 34.57 per A share and HKD 18.60 per H share, and the H-share election period runs from 15 to 17 September (closing 4:30 p.m. on 17 September). CICC H shares closed at HKD 21.90 on 4 September, a premium of about 17.74% over the exercise price, and exercising the election may result in losses.
On 7 September 2026, VIVA GOODS (00933.HK) announced that its wholly-owned subsidiary had further acquired 19,231,000 shares in Li Ning (02331.HK) on the open market through the Stock Exchange for a total consideration of approximately HKD 263,736,000 (approximately HKD 13.71 per share), raising its stake from approximately 18.30% to 19.04%. As two applicable percentage ratios exceed 5% but remain below 25%, the acquisition constitutes a discloseable transaction, while the company's two earlier rounds of acquisitions were each classified as major transactions.
On 7 September 2026, UNITED LAB (03933.HK) voluntarily announced that UBT251 injection, a Class 1 innovative drug developed by its wholly-owned subsidiary United Bio-Tech, had completed first participant dosing in the Phase III clinical study for type 2 diabetes in China, which comprises UNIGUIDE-1 (360 participants, placebo-controlled) and UNIGUIDE-2 (956 participants, semaglutide-controlled). UBT251 is a long-acting GLP-1/GIP/GCG triple receptor agonist; the company is the first in China and the second globally to obtain clinical approval for such an agonist prepared by chemical synthesis of peptides, and entered into an exclusive license agreement with Novo Nordisk in March 2025.
On 7 September 2026, LDROBOT (01236.HK) voluntarily announced that its shares had been included in the eligible securities lists of Stock Connect under both the Shanghai-Hong Kong and Shenzhen-Hong Kong schemes, effective from the same day, following the notices issued by the two exchanges. The company believes the inclusion will enhance its capital market recognition, broaden its shareholder base and improve share liquidity.
On 7 September 2026, OCT (ASIA) (03366.HK) announced that it plans to dispose of the entire equity interest in OCT (Changshu) Investment, an indirect wholly-owned subsidiary engaged in industrial park operation and leasing, through an open listing process on the Beijing Equity Exchange, with the potential disposal expected to constitute a major transaction under Chapter 14 of the Listing Rules if materialized. The target recorded revenue of RMB 3.24 million and net profit of RMB 0.37 million in H1 2026, with total assets of RMB 80.81 million and total liabilities of RMB 6.96 million as of 30 June 2026. The disposal is at the preliminary information disclosure stage, subject to conditions precedent including shareholders' approval, and is independent of the potential disposal of OCT (Changshu) Industrial Development announced on the same date.
On 7 September 2026, CM BANK (03968.HK) announced that assistant general manager Mr. Wang Xinghai had resigned due to work reasons, effective from the same day. He confirmed no disagreement with the board and no unfulfilled public commitments, will no longer hold any position in the company or its controlled subsidiaries after his resignation, and has completed the handover of his duties.
On 7 September 2026, CSPC PHARMA (01093.HK) voluntarily announced the official initiation of the Phase II clinical trial of SYH2085 tablets for uncomplicated influenza in adults at the first center in China. SYH2085 is a Class 1 chemical small-molecule inhibitor targeting the PA subunit of the influenza virus RNA polymerase; the group obtained an NMPA Clinical Trial Approval Notice in December 2025, and Phase I data have preliminarily validated its safety and pharmacokinetic/pharmacodynamic profiles, while the multicenter, randomized, double-blind, placebo-controlled Phase II study is now recruiting and screening participants.
On 7 September 2026, CENTRALCHINA MT (09982.HK) announced that executive director Ms. Liu Lin and company secretary and authorized representative Mr. Xie Ziqian had resigned, both effective from the same day. Following Mr. Xie's resignation, the company is temporarily non-compliant with Rules 3.05 and 3.28 of the Listing Rules; the board will identify replacements as soon as possible, with executive director Mr. Wang Kai and external company secretarial service providers and/or legal advisers assisting with compliance matters in the interim.
On 7 September 2026, MICROTECH MED-B (02235.HK) voluntarily announced that its next-generation patch-style continuous glucose monitoring system AiDEX G9 had obtained marketing approval from the NMPA, featuring an innovative change in technical architecture and comprehensive upgrades in size, lightweight design and wearing comfort over the first-generation product. Citing the IDF Diabetes Atlas 2025, the announcement noted that approximately 148 million Chinese adults aged 20-79 were living with diabetes in 2024, ranking first globally, with 274 million adults with prediabetes.
On 7 September 2026, SBP GROUP (01177.HK) voluntarily announced that TQC3721 dry powder inhaler, a PDE3/4 inhibitor developed by its subsidiary Chia Tai Tianqing, had two Phase I datasets presented at ERS 2026: a dose-ranging study in 72 COPD patients showed dose-dependent improvements in peak FEV1 at Day 9 (from 300.0 mL in the 125 μg group to 497.0 mL in the 1000 μg group), and a proof-of-concept study of the combination with glycopyrronium bromide (40 patients) showed clinically meaningful improvements versus the IND/GLY control, with FEV1 trough improving 203 mL and peak 110 mL from baseline. The nebulized suspension formulation of TQC3721 is in Phase III in China and has received CDE breakthrough therapy designation.
On 7 September 2026, TIMES CHINA (01233.HK) announced its unaudited operational data for the eight months ended 31 August 2026, recording contracted sales (including contracted sales of joint venture projects) of approximately RMB 205 million with contracted GFA of approximately 16,900 sq.m. in August, and cumulative contracted sales of approximately RMB 2.237 billion with cumulative contracted GFA of approximately 219,700 sq.m. for the eight-month period.
On 7 September 2026, HENGRUI PHARMA (01276.HK) announced that it had received NMPA Clinical Trial Approval Notices for HRS-6209 capsules and HRS-4508 tablets, approving an open-label, multicenter Phase Ib/II study of HRS-6209 in combination with other anti-tumor therapies in advanced unresectable or metastatic breast cancer and of HRS-9813 in advanced solid tumors. HRS-6209 is a novel selective CDK4 inhibitor that has advanced into Phase II, and HRS-4508 tablets are a novel selective tyrosine kinase inhibitor; cumulative R&D investment in the two projects amounts to approximately RMB 160.9 million and RMB 96.7 million respectively.
